Search
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnThe same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype
Isoflavone
go.drugbank.com/drugs/DB12007ApprovedInvestigationalWithdrawnSoybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Cilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCompared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium … This drug is approved in China, Japan, Korea, India, and several countries in the European Union.[A31970]
Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedAlpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049] … These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawnIt is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one … [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication.
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnTyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.
Prochlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. … Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.[L6640]
Synonyms: Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine, N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazineZucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.